Vigilant Capital Management LLC Decreases Position in Pfizer, Inc. (PFE)
Vigilant Capital Management LLC reduced its stake in Pfizer, Inc. (NYSE:PFE) by 1.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,475 shares of the biopharmaceutical company’s stock after selling 688 shares during the period. Vigilant Capital Management LLC’s holdings in Pfizer were worth $1,360,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Asset Planning Services Ltd. raised its holdings in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the 1st quarter worth approximately $121,000. Patten Group Inc. raised its holdings in Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 252 shares during the last quarter. Acropolis Investment Management LLC raised its holdings in Pfizer by 6.7% during the 2nd quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 352 shares during the last quarter. Finally, Kimelman & Baird LLC bought a new position in Pfizer during the 1st quarter worth approximately $203,000. Institutional investors and hedge funds own 68.99% of the company’s stock.
In other Pfizer news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now owns 124,774 shares in the company, valued at $4,242,316. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock worth $15,813,961 over the last quarter. 0.06% of the stock is currently owned by company insiders.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 EPS.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. Pfizer’s payout ratio is presently 94.12%.
Several analysts have recently commented on PFE shares. Jefferies Group LLC reissued a “neutral” rating and issued a $34.00 price target on shares of Pfizer in a research report on Friday, June 16th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $38.10.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.